Among autoantibodies, the development of autoantibodies associated with antiphospholipid syndrome (APS), those targeting antiphospholipid antigens, autoantibodies directed against cardiolipin (aCL-IgG), and β2-glycoprotein I (anti-β2GPI), and lupus anticoagulants (LAC), have been reported in patients with rheumatoid arthritis treated with TNFi9,10. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.